Pfizer Inc. $PFE Shares Sold by Confluence Wealth Services Inc.

Confluence Wealth Services Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 26.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,193 shares of the biopharmaceutical company’s stock after selling 22,200 shares during the period. Confluence Wealth Services Inc.’s holdings in Pfizer were worth $1,574,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. State Street Corp increased its holdings in shares of Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Northern Trust Corp increased its holdings in shares of Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC grew its holdings in Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after acquiring an additional 897,786 shares during the period. Legal & General Group Plc raised its position in Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after acquiring an additional 3,296,415 shares in the last quarter. Finally, Amundi raised its position in Pfizer by 10.8% in the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after acquiring an additional 4,043,413 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.6%

Pfizer stock opened at $26.65 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The firm has a market capitalization of $151.53 billion, a price-to-earnings ratio of 19.59 and a beta of 0.43. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The stock’s fifty day moving average is $27.24 and its two-hundred day moving average is $26.06.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.63 earnings per share. Analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer’s dividend payout ratio is 126.47%.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. HSBC increased their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Guggenheim increased their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Royal Bank Of Canada reiterated an “underperform” rating and issued a $25.00 price objective on shares of Pfizer in a research report on Monday. Finally, UBS Group increased their price objective on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.48.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China pre-orders and commercialization progress for Pfizer’s GLP-1 weight‑management drug (Xianweiying) increase near‑term revenue optionality in a large market and validate the obesity franchise expansion. China pre-order Reuters
• Positive Sentiment: PF-08653944 (GLP‑1) continues to show promise — Phase 2b data supporting a once‑monthly dosing profile and a program threaded into >20 obesity trials (10 Phase 3 targeted in 2026) point to a potential multi‑year growth engine beyond legacy COVID products. Yahoo GLP-1 article
• Positive Sentiment: Advances in early‑stage programs: completion of a Phase 1 heart‑failure study in China and launches/advances for PF‑08653944 liver and obesity gastric‑emptying studies broaden pipeline visibility and create long‑term optionality if later‑stage data succeed. Heart failure Phase 1 Liver study Gastric emptying study
• Positive Sentiment: Dividend: Pfizer declared a $0.43 quarterly dividend (350th consecutive quarter), which supports yield‑seeking investors and underpins the stock’s income appeal. Dividend press release
• Neutral Sentiment: New Phase 1 cancer trial start and upcoming ASCO oncology presentations add potential upside if data impress, but early‑stage readouts are uncertain and timing is multi‑quarter. New Phase 1 cancer trial ASCO preview
• Neutral Sentiment: Consensus analyst view remains mixed/neutral (consensus “Hold”), leaving the stock sensitive to headline catalysts and quarter‑to‑quarter beats. Analyst consensus
• Negative Sentiment: Pipeline pruning: Pfizer ended a Phase 1 cancer trial — a near‑term negative for oncology optionality and a reminder that not all internal programs will reach later stages. Trial termination
• Negative Sentiment: Analyst downgrades/pressure: Barclays reiterated a “sell” and RBC/others issued underperform ratings — these views can drive short‑term selling and weigh on investor sentiment. Barclays sell note RBC underperform
• Negative Sentiment: Recent coverage noted the stock has recently fallen on mixed headlines and earnings‑cycle positioning, reflecting a market focus on near‑term growth vs. long‑term pipeline bets. Stock sinks article

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.